Obstetric and Gynecologic Imaging

What Imaging Is Best for Ovarian Cancer Screening in High-Risk Postmenopausal Women?

·
What Imaging Is Best for Ovarian Cancer Screening in High-Risk Postmenopausal Women?

A 68-year-old woman with a known BRCA1 mutation presents for her annual wellness visit. She is asymptomatic and has been postmenopausal for over a decade. Her mother and aunt both had ovarian cancer. Given her high-risk status, you know that surveillance is indicated, but the question is which imaging study to order. This is a common and high-stakes decision, as the goal is to detect a potential malignancy at its earliest, most treatable stage without subjecting the patient to unnecessary procedures. This article details the specific imaging workflow for high-risk, postmenopausal ovarian cancer screening. For this scenario, the American College of Radiology (ACR) rates pelvic ultrasound, including `US color Doppler ovaries`, as May be appropriate.

Who Fits This Clinical Scenario?

This guidance applies specifically to postmenopausal adult women who are considered at high risk for developing ovarian cancer. This risk is not based on symptoms but on established predisposing factors. A patient fits this scenario if she meets both criteria:

1. Postmenopausal Status: The patient has ceased menstruating, typically defined as 12 consecutive months without a period. This is a critical distinction, as the appearance of the ovaries and the background risk of benign functional cysts change significantly after menopause.

2. High-Risk Profile: This category is reserved for individuals with a substantially elevated lifetime risk, most commonly due to:

  • Known pathogenic mutations in genes like BRCA1 or BRCA2.
  • A personal or family history consistent with hereditary cancer syndromes such as Lynch syndrome (hereditary non-polyposis colorectal cancer) or Peutz-Jeghers syndrome.
  • A strong family history of ovarian, breast, colon, or endometrial cancer, even without a known genetic mutation, that places them in a high-risk tier based on validated models.

This workflow is not for average-risk postmenopausal women, for whom population-based screening is not recommended due to a high rate of false positives. It also does not apply to premenopausal women, whether high-risk or average-risk, as their ovarian physiology and the appropriate screening protocols differ.

What Diagnoses Are You Working Up in This Scenario?

In asymptomatic high-risk screening, the primary goal is the early detection of a potentially curable malignancy. The differential diagnosis for an adnexal finding on imaging in this population ranges from benign to life-threatening.

Epithelial Ovarian Carcinoma: This is the principal target of screening. The vast majority of ovarian cancers are epithelial in origin. In a high-risk postmenopausal woman, any new solid or complex cystic adnexal mass is highly suspicious for malignancy until proven otherwise. The goal of screening is to identify these cancers at Stage I or II, when survival rates are significantly higher.

Benign Adnexal Lesions: Even in postmenopausal women, benign findings can occur. These include simple serous cysts, which are often benign but require careful evaluation and follow-up. Other benign entities like cystadenomas or fibromas can also be detected. Ultrasound helps differentiate these from more suspicious lesions based on morphologic features.

Borderline Tumors (Low Malignant Potential): These are epithelial tumors that are not fully malignant but have a higher potential for recurrence and progression than benign tumors. They often appear as complex cysts with papillary projections on ultrasound and represent a critical finding, as their management differs from both clearly benign and invasive malignant masses.

Non-Ovarian Pathology: The adnexa includes the fallopian tubes and surrounding connective tissue. Imaging may reveal pathology unrelated to the ovary, such as a hydrosalpinx (fluid-filled fallopian tube) or a peritoneal inclusion cyst. While often benign, these findings must be correctly identified to avoid an unnecessary workup for ovarian cancer.

Why Is Pelvic Ultrasound the Cornerstone of Screening for High-Risk Women?

For high-risk postmenopausal women, a comprehensive pelvic ultrasound is the foundational imaging modality for screening. The ACR rates `US pelvis transvaginal`, `US pelvis transabdominal`, and `US color Doppler ovaries` as May be appropriate. In practice, these are components of a single, complete examination designed to provide a detailed morphological assessment of the ovaries and adnexa.

The rationale for this approach is based on a balance of diagnostic capability, safety, and accessibility. Transvaginal ultrasound offers high-resolution images of the ovaries, allowing for detailed characterization of any masses, including their size, internal architecture (simple vs. complex cyst), presence of solid components, and septations. Color Doppler is then used to assess vascularity within any identified lesion. Increased or chaotic blood flow is a concerning feature for malignancy.

This combined ultrasound approach is effective for detecting structural abnormalities and carries no radiation risk (adult RRL=O 0 mSv). Its high sensitivity for adnexal masses makes it the ideal first-line screening tool.

Why are other advanced imaging modalities not used for screening?

  • MRI Pelvis without and with IV contrast is rated Usually not appropriate for screening. While MRI provides excellent soft tissue contrast and is a superior problem-solving tool for characterizing an indeterminate mass found on ultrasound, it is too expensive and time-intensive for routine screening. Its role is in characterization, not initial detection.
  • CT Abdomen and Pelvis with IV contrast is also rated Usually not appropriate. CT exposes the patient to significant ionizing radiation (adult RRL=☢☢☢ 1-10 mSv) and has lower sensitivity than transvaginal ultrasound for detecting and characterizing small or subtle ovarian lesions. Its primary role is in staging confirmed cancer, not screening for it.

What’s Next After Pelvic Ultrasound? Downstream Workflow

The results of the screening ultrasound dictate the next steps in a well-defined clinical pathway, almost always in consultation with a gynecologic oncologist.

If the study is clearly positive (suspicious mass): If the ultrasound reveals a solid adnexal mass, a complex cyst with solid components, or significant vascularity, the finding is highly suspicious for malignancy. The patient should be referred urgently to a gynecologic oncologist. Pre-operative workup may include an MRI for further characterization and surgical planning, along with serum tumor markers. The definitive diagnosis is made through surgical excision and histopathology.

If the study is negative (normal atrophied ovaries): A normal result is reassuring but does not eliminate future risk. The patient should continue her prescribed high-risk surveillance protocol. This typically involves alternating pelvic ultrasound with serum CA-125 testing every 6 months, though specific institutional and society guidelines may vary.

If the study is indeterminate (e.g., a new simple cyst): The appearance of a simple, thin-walled, anechoic cyst without solid components is a common indeterminate finding. While most are benign, they require follow-up in a postmenopausal woman. The next step is typically a short-interval follow-up ultrasound in 3-6 months to ensure stability or resolution. Any growth or development of complex features on the follow-up scan would trigger a reclassification to “suspicious” and prompt a referral to gynecologic oncology.

Pitfalls to Avoid (and When to Get Help)

Navigating high-risk ovarian cancer screening requires careful attention to detail to avoid common errors that can impact patient outcomes.

  • Underestimating a “Simple” Cyst: In a postmenopausal woman, any new adnexal cyst warrants respect. Do not dismiss it without a clear follow-up plan.
  • Incomplete Ultrasound: Relying solely on a transabdominal view is insufficient. Transvaginal imaging is essential for the detailed ovarian morphology needed in high-risk screening.
  • Screening the Wrong Patient: Applying this high-intensity screening protocol to average-risk women can lead to a cascade of unnecessary anxiety, testing, and surgery due to the high rate of false positives.
  • Ignoring the Serum Marker: Screening is most effective when imaging is combined with serum CA-125 levels. A rising CA-125, even with a normal-appearing ultrasound, is a major red flag.

If any solid or complex cystic adnexal mass is identified on ultrasound in a high-risk postmenopausal patient, the situation requires immediate escalation. This patient should be referred to a gynecologic oncologist for further management.

Related ACR Topics and Tools

For a comprehensive overview of all clinical variants related to ovarian cancer screening, including protocols for premenopausal and average-risk patients, please see our parent guide. For other tools to assist in ordering the correct imaging study, the resources below are available.

Frequently Asked Questions

Why is routine ovarian cancer screening not recommended for average-risk postmenopausal women?

For average-risk women, large clinical trials have shown that screening with ultrasound and CA-125 leads to a high number of false-positive results. This causes significant patient anxiety and results in many unnecessary surgeries for benign conditions, without a clear mortality benefit. The risks of intervention are considered to outweigh the benefits for this population.

What is the role of serum CA-125 in this high-risk screening scenario?

In high-risk women, serum CA-125 is typically used in conjunction with transvaginal ultrasound. While CA-125 can be elevated in many benign conditions and is not a perfect marker, a rising trend over time is a significant warning sign for ovarian cancer. The combination of both tests improves the overall sensitivity of the screening program.

If a patient had a risk-reducing salpingo-oophorectomy, does she still need screening?

No. A risk-reducing bilateral salpingo-oophorectomy (removal of both ovaries and fallopian tubes) is the most effective method for preventing ovarian cancer in high-risk women. After this procedure, the risk of primary peritoneal cancer remains (a related but rare cancer), but routine imaging screening is generally not performed.

How often should high-risk postmenopausal women undergo screening?

Most guidelines recommend screening every 6 months for high-risk women who have not undergone prophylactic surgery. This often involves alternating transvaginal ultrasound with a serum CA-125 test, meaning the patient gets one of the two tests every six months. However, specific protocols can vary, and the plan should be managed by a specialist familiar with high-risk surveillance.

Can MRI replace ultrasound for screening if a patient prefers it?

No, MRI is not a replacement for ultrasound in the screening setting. The ACR designates MRI as ‘Usually not appropriate’ for screening due to its high cost, longer scan time, and lack of evidence demonstrating superiority over ultrasound for initial detection. Its primary role is as a problem-solving tool to better characterize a suspicious finding that was first identified on an ultrasound.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 26, 2026